Kendle International

Kendle (Nasdaq: KNDL) is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions – from “first-in-human” studies through market launch and surveillance – to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. Kendle has a 25-year history of serving customers, both large and small, and with a diversity of compounds, which means that our expertise spans every major therapeutic area. We are focused on growing Phase I-IV clinical development expertise in the top five therapeutic areas expected to represent 70 percent of R&D spending by 2009: cardiology, oncology, antibiotics and antivirals, central nervous system and arthritis/inflammation. With headquarters in Cincinnati, Ohio and approximately 3,000 associates worldwide, Kendle has conducted clinical trials or provided regulatory services in 80 countries. Our mission Kendle is a global clinical research organization that provides the biopharmaceutical industry with outstanding strategy as well as a full complement of quality clinical development and regulatory services to accelerate the drug development process. We live our “Real people. Real results.®” statement every day as we work in partnership with companies to help speed their drugs to market, making a real difference to the quality of life of people around the world.

Contact Details: 1200 Carew Tower 441 Vine Street Cincinnati OH 45202 United States of America Tel: +1 513 381 5550 Fax: +1 513 381 5870 Email: info@kendle.com WWW: www.kendle.com/

Loading...

Press Releases on Kendle International:
Kendle Announces Third Quarter 2009 Results	4th November, 2009	Kendle International Inc.	CINCINNATI, Nov. 4 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today reported solid net income of $8.8 million or $0.59 per diluted
Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting	2nd November, 2009	Kendle International Inc.	CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of J. Michael Sprafka, MPH, PhD, as
Kendle's TrialEAS(TM) Electronic Adjudication System Named 'Best Technological Development in Clinical Trials - Software Solution' in GCPj Clinical Research Excellence Awards	21st October, 2009	Kendle International Inc.	CINCINNATI, Oct. 21 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced its proprietary electronic adjudication system
Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast	13th October, 2009	Kendle International Inc.	CINCINNATI, Oct. 13 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) announced today that it will release its third quarter 2009 financial results after the market closes on Wednesday, Nov. 4, 2009.
Kendle Appoints John Needham Executive Director and Global Head, Patient Enrollment Strategy	5th October, 2009	Kendle International Inc.	CINCINNATI, Oct. 5 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of John Needham as Executive Director

BioNews Results for Kendle International:
Business development role strengthened as Grant Barnett joins growing Synexus team	PharmiWeb:  Nov 19 2009 1:43AM Matching: kendle international
Business Development Role Strengthened as Grant Barnett Joins Growing Synexus Team	Genetic Engineering News:  Nov 18 2009 12:03PM Matching: kendle international
Kendle beats outlook for 3Q	San Francisco Business Times:  Nov 5 2009 6:21PM Matching: kendle international
Kendle Announces Third Quarter 2009 Results	TickerTech.com:  Nov 4 2009 10:21PM Matching: kendle international
Kendle's TrialEAS(TM) Electronic Adjudication System Named 'Best Technological Development in Clinical Trials	Freshnews.com:  Oct 22 2009 3:40AM Matching: kendle international
Promote your company here: BioNewsCast - Press Release Distribution	→View more Kendle International news.

Kendle International Clinical Trials:
Ribavirin Pregnancy Registry

Kendle International (KNDL) Financial information Links from Barchart
KNDL Quote from from Barchart.com
KNDL Chart from from Barchart.com
KNDL Profile from from Barchart.com
KNDL Opinion from from Barchart.com
→View more Kendle International finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 548 times since April 2007, the link to the organisation's website has been followed 68 times

Recent Search Terms used to find this page: Kendle International Inc mission statement | Kendle International Inc mission statement | bioportfolio kendle | kendle or kendel pharma* | kendle or kendel pharma* | solution to kendle international financing strategy | kendle international history | clinical development kendle international 07 march 2009 | .

Search for more companies in Cincinnati

Search for more companies in OH

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Kendle International